162 related articles for article (PubMed ID: 22113498)
1. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.
Bu R; Uddin S; Ahmed M; Hussain AR; Alsobhi S; Amin T; Al-Nuaim A; Al-Dayel F; Abubaker J; Bavi P; Al-Kuraya KS
Mol Med; 2012 Mar; 18(1):167-77. PubMed ID: 22113498
[TBL] [Abstract][Full Text] [Related]
2. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
Uddin S; Hussain AR; Ahmed M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Pathol; 2011 Dec; 179(6):3032-44. PubMed ID: 21978492
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
[TBL] [Abstract][Full Text] [Related]
5. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
7. Scatter factor protects tumor cells against apoptosis caused by TRAIL.
Fan S; Meng Q; Laterra JJ; Rosen EM
Anticancer Drugs; 2010 Jan; 21(1):10-24. PubMed ID: 19823077
[TBL] [Abstract][Full Text] [Related]
8. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
[TBL] [Abstract][Full Text] [Related]
11. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
You H; Ding W; Dang H; Jiang Y; Rountree CB
Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
[TBL] [Abstract][Full Text] [Related]
12. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
13. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
14. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells.
Jo EB; Lee YS; Lee H; Park JB; Park H; Choi YL; Hong D; Kim SJ
BMC Cancer; 2019 May; 19(1):496. PubMed ID: 31126284
[TBL] [Abstract][Full Text] [Related]
17. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
[TBL] [Abstract][Full Text] [Related]
18. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
Lau PC; Wong EY
Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
20. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
